&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-04-28, 20:23

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-02-19, 19:05

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Lesley Moroney

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-22, 19:00

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Kaitlyn Granata

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-09, 22:45

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-27, 14:05

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Britney MacDevitt

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-26, 19:10

A21 Launches Host Applications for Walk for Freedom 2024
Bradley Crotty

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-20, 21:46

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
Clarita Gooden

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-03-04, 03:03

Space Tea Set to Attend Natural Products Expo West 2023

Natural Products Expo West is the leading trade show in the natural, organic and healthy products industry, drawing buyers from retailers of all sizes...

Popular Posts